Last edition
News about "ORZEYFUL"
Japan Approves Takeda's ORZEYFUL (Oveporexton) for Narcolepsy Type 1
Japan approves ORZEYFUL (oveporexton) as the first and only medicine targeting the underlying cause of narcolepsy type 1, following positive phase 3 results.
ORZEYFUL | 24/08/2026 | By News Bureau | 105
US FDA Approves Takeda's ORZEYFUL for Narcolepsy Type 1
US Food and Drug Administration (FDA) approves Takeda's ORZEYFUL (oveporexton), the first orexin therapy to treat the underlying cause of Narcolepsy Type 1 in adults.
ORZEYFUL | 07/08/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy